Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BIOSGN.STthis companyBiosergen AB	SEK 0.49	-20.76×	72.03×	0×	-20.37×	34.2%	0.0%	0.0%	0.0%	-347.0%	-351.9%	-4.3%	0×	0.38×	-4,139.3×	2.46×	0.0%	2	-8.67	—	—
ACTI.STActive Biotech AB	SEK 3.45	-166.06×	111.47×	0×	-170.4×	-98.9%	0.0%	0.0%	0.0%	-67.1%	-65.6%	-0.5%	0.03×	1.76×	0×	4.66×	0.0%	3	4.44	2	C+
ARCOMA.STArcoma AB	SEK 8.50	20.97×	1.41×	0.8×	4.36×	-14.6%	5.2%	6.6%	3.8%	6.7%	9.3%	12.5%	0×	-2.2×	73.58×	3.49×	0.0%	6	6.68	3	B+
BIOVIC-B.STBiovica International AB (publ)	SEK 0.32	-1.17×	0.95×	6.14×	-0.26×	-1052.3%	-523.5%	-523.5%	-522.1%	-80.9%	-76.5%	-77.0%	0.05×	1.07×	-176.89×	4.3×	0.0%	3	-9.24	2	C
NICA.STNanologica AB (publ)	SEK 0.17	-1.34×	3.04×	3.26×	-2.51×	-1306.2%	-233.8%	-222.4%	-242.8%	-226.5%	-64.6%	-59.3%	0.95×	-0.52×	-9.99×	1.85×	0.0%	3	-1.86	4	A-
NXTCL.STNextCell Pharma AB	SEK 0.25	-2.57×	1.36×	8.24×	-1.58×	-4580.5%	-328.0%	-328.0%	-321.3%	-52.9%	-50.3%	-47.7%	0×	1.19×	-13,802.15×	10.02×	0.0%	0	-5.87	1	C-
Peer median	—	-1.34×	1.41×	3.26×	-1.58×	-1052.3%	-233.8%	-222.4%	-242.8%	-67.1%	-64.6%	-47.7%	0.03×	1.07×	-9.99×	4.3×	0.0%	3	-1.86	2	—